Skip to main content

Advertisement

Table 3 Univariate and multivariate analysis for local control and overall survival according to patient and tumor characteristics

From: The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases

  Univariate   Multivariate  
  HR (CI) p-value HR (CI) p-value
Local control
Prior CTxa 2.19 (1.23–3.91) 0.008 2.19 (1.18–4.06) 0.13
Histology (CRC) 1.99 (1.31–3.04) 0.001 1.71 (1.04–2.80) 0.03
Histology (BCa) 0.53 (0.25–1.13) 0.10 0.45 (0.19–1.02) 0.06
Histology (NSCLC) 0.86 (0.26–2.85) 0.81 0.67 (0.19–2.35) 0.54
GTV Volumec 1.004 (1.002–1.005) < 0.001 –  
PTV Volumec 1.002 (1.001–1.003) < 0.001 1.001 (1.00–1.002) 0.003
BED Isocenterc 0.993 (0.989–0.997) < 0.001 0.99 (0.98–1.00) 0.002
BED prescriptionc 0.72 (0.51–1.01) 0.003 1.00 (0.99–1.01) 0.970
Advanced Motion managementa 0.46 (0.29–0.72) < 0.001 0.57 (0.33–0.96) 0.04
Before 2003a 1.50 (1.04–2.16) 0.031 1.02 (0.61–1.70) 0.932
Overall survival
KIc 0.69 (0.51–0.94) 0.02 0.74 (0.53–0.98) 0.06
Gender 0.80 (0.63–1.01) 0.06 0.76 (0.54–1.06) 0.10
Histology (CRC) 0.61 (0.46–0.79) < 0.001 0.64 (0.45–0.92) 0.01
Histology (BCa) 0.52 (0.36–0.76) < 0.001 0.60 (0.36–0.99) 0.05
Histology (NSCLC) 1.42 (0.87–2.33) 0.16 1.14 (0.64–2.07) 0.65
Prior CTxa 0.91 (0.65–1.27) 0.58 1.17 (0.76–1.80) 0.47
Extrahepatic statusb 0.81 (0.60–1.1) 0.18 0.83 (0.49–1.43) 0.52
Solitarya 0.73 (0.57–0.92) 0.007 1.12 (0.61–2.03) 0.72
# of liver metastases (1 vs. 2–4) 0.94 (0.72–1.23) 0.65 0.80 (0.52–1.23) 0.32
GTV Volumec 1.003 (1.002–1.004) < 0.001 –  
PTV Volumec 1.002 (1.001–1.002) < 0.001 1.002 (1.001–1.003) < 0.001
Local recurrence after SBRTa 0.88 (0.68–1.51) 0.36 0.82 (0.56–1.19) 0.29
BED isocenterc 0.997 (0.994–1.00) 0.06 1.00 (0.99–1.004) 0.97
  1. CTx chemotherapy, BCa breast cancer, BED biologically effective dose, GTV gross tumor volume, PTV planning target volume, PS performance status, HR hazard ratio, CI 95% confidence interval), CRC corolrectal caner, NSCLC non-small cell lung cancer
  2. abinary coded variables with yes vs. no; bcomplete remission/stable disease vs progressive disease; cvolume and minimum biologically effective dose as continuous variables
Back to article page